Gastroenterology

Liver Cirrhosis

Also known as: Hepatic Cirrhosis, End-Stage Liver Disease

Extensive scarring of the liver caused by long-term damage, leading to liver failure, portal hypertension, and severe systemic complications.

Source: American Association for the Study of Liver Diseases (AASLD)

Updated: Aug 16, 2026

3,871 Views

Red Flag Warning & Emergency Situations

Hematemesis or melena (suggests variceal bleed)
Fever, diffuse abdominal pain, and altered mental status (Spontaneous Bacterial Peritonitis)
Sudden onset of severe confusion or coma

Emergency Management: Acute variceal hemorrhage: Requires immediate resuscitation, Octreotide infusion (50 mcg bolus, 50 mcg/hr), IV Ceftriaxone (1g/day) for SBP prophylaxis, and urgent endoscopy (within 12 hours) for banding.

Core Definition:

Liver cirrhosis is the late stage of progressive hepatic fibrosis characterized by the distortion of the hepatic architecture and the formation of regenerative nodules. It represents the irreversible end result of various chronic liver insults.

Detailed Overview

Cirrhosis leads to severe hepatic dysfunction and portal hypertension. The loss of functional hepatocyte mass causes synthetic failure (impaired albumin and clotting factor production) and detoxification failure (hepatic encephalopathy). Portal hypertension drives the formation of ascites, esophageal varices, and splenomegaly. It is a major cause of morbidity and is highly predisposed to the development of Hepatocellular Carcinoma (HCC).

Epidemiology & Demographics

Prevalence is approximately 0.15% to 0.27% of the US population. The 10-year mortality rate ranges from 34% to 66%. Higher prevalence in men and individuals aged 45-54.

Etiological Mechanism

The most common causes in the developed world are Chronic Hepatitis C, Alcohol-Associated Liver Disease (ALD), and Nonalcoholic Steatohepatitis (NASH).

Primary Causes

Chronic HCV, excessive chronic alcohol intake, NASH/metabolic syndrome, Chronic HBV, Hemochromatosis, Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis, and Alpha-1 antitrypsin deficiency.

Heavy Alcohol Consumption: Drinking > 40g (women) to > 60g (men) of alcohol daily for over 10 years.
Metabolic Syndrome: Obesity, Type 2 Diabetes, and dyslipidemia strongly drive NASH progression to cirrhosis.
IV Drug Use: High risk for acquiring Hepatitis B and C viruses.

Chronic liver injury leads to hepatocyte necrosis and the release of inflammatory cytokines. Kupffer cells activate hepatic stellate cells in the Space of Disse. Activated stellate cells transition into myofibroblasts and hyper-secrete extracellular matrix, primarily Type I and III collagen. This diffuse fibrosis disrupts the sinusoidal architecture, increasing intrahepatic resistance (portal hypertension). Surviving hepatocytes proliferate to form regenerative nodules, completely distorting liver anatomy.

Characteristic Clinical Presentation

Fatigue and Weakness: Profound, debilitating fatigue, often the earliest and most common symptom.
Abdominal Distension: Increasing girth due to the accumulation of ascitic fluid in the peritoneal cavity.
Confusion/Lethargy: Episodes of altered mental status due to hepatic encephalopathy from ammonia build-up.

Physical Examination Signs

Spider angiomas and palmar erythema (due to altered estrogen metabolism)
Jaundice and scleral icterus
Caput medusae (dilated periumbilical veins) and shifting dullness (ascites)
Asterixis (flapping tremor of outstretched hands)

Clinical Risk: Uncontrolled or untreated conditions may progress to the following complications:

Portal Hypertension: Leading to esophageal and gastric varices, which can rupture and cause fatal hemorrhage.
Hepatic Encephalopathy: Neuropsychiatric abnormalities due to liver failure to clear neurotoxins (ammonia).
Hepatocellular Carcinoma (HCC): Primary liver cancer; cirrhosis is the biggest risk factor.

Diagnostic Criteria & Guidelines

Diagnosed via a combination of clinical, laboratory, and imaging findings. The gold standard is a liver biopsy showing nodular regeneration surrounded by fibrous septa. However, it is clinically diagnosed via non-invasive means like transient elastography (FibroScan stiffness > 12.5 kPa) coupled with compatible labs (thrombocytopenia, prolonged PT/INR).

Differential Diagnosis

Severe Acute Alcoholic Hepatitis
Acute Liver Failure (e.g., Acetaminophen toxicity)
Budd-Chiari Syndrome
Right-Sided Heart Failure (Cardiac Cirrhosis)

Laboratory Tests & Biomarkers

Platelet Count: < 150,000 /microL (often < 100,000 due to splenic sequestration)
Albumin: < 3.5 g/dL (decreased synthesis)
PT / INR: Elevated (e.g., INR > 1.2) due to decreased production of coagulation factors
Total Bilirubin: Elevated (> 2.0 mg/dL)

Imaging Modalities & Findings

Ultrasound: Nodular liver surface, coarse echotexture, splenomegaly (>12 cm), and reversal of portal vein flow.
CT/MRI Abdomen: Hypertrophy of the caudate lobe, atrophy of the right lobe, and presence of portosystemic collaterals.

Compensated Cirrhosis
Asymptomatic or non-specific symptoms; normal or mildly abnormal liver tests. Median survival > 12 years.
Decompensated Cirrhosis
Presence of complications: ascites, variceal hemorrhage, encephalopathy, or jaundice. Median survival drops to 2 years.

First-Line Treatment:

Management of complications. Ascites: Sodium restriction (<2000 mg/day) and Spironolactone (100 mg PO daily) with Furosemide (40 mg PO daily). Encephalopathy: Lactulose 20-30g PO titrated to 2-3 soft bowel movements daily. Varices: Non-selective beta-blockers (Nadolol 20-40 mg PO daily) or endoscopic band ligation.

Second-Line & Adjunctive Therapy

Refractory Ascites: Large-volume paracentesis with IV Albumin replacement (8g per liter of fluid removed), or TIPS (Transjugular Intrahepatic Portosystemic Shunt). Refractory Encephalopathy: Rifaximin 550 mg PO BID added to Lactulose.

Surgical & Procedural Management

Orthotopic Liver Transplantation is the only definitive cure for decompensated cirrhosis (MELD score > 15).

Recommended Lifestyle Changes

Absolute abstinence from alcohol and hepatotoxic drugs (e.g., excessive acetaminophen).
Dietary sodium restriction (< 2 grams/day) to manage ascites.
High-protein, high-calorie diet with frequent small meals to prevent muscle wasting (sarcopenia).

Patient Counseling & Advice

Warn the patient that cirrhosis is irreversible but its progression can be slowed by removing the insult. Educate on the critical importance of cancer screening and medication adherence to prevent decompensation.

Follow-Up & Monitoring Schedule

HCC screening: Liver ultrasound every 6 months, with or without serum Alpha-Fetoprotein (AFP). EGD every 1-3 years to screen for esophageal varices. Calculate MELD-Na score routinely.

Preventive Strategies

Vaccination against Hepatitis A and B. Aggressive treatment of chronic HCV with direct-acting antivirals. Weight loss and glycemic control for NASH. Alcohol cessation.

Highly dependent on the stage. Measured by the Child-Pugh Score and MELD-Na score. Child-Pugh Class C has a 1-year survival rate of < 50% without transplantation.

Frequently Asked Questions

No, once cirrhosis (widespread scarring) is established, it is generally considered irreversible. However, treating the underlying cause can prevent it from getting worse.

Cirrhosis dramatically increases the risk of liver cancer. Ultrasounds every 6 months are crucial to catch tumors when they are small and curable.

Authoritative Sources & Evidence References

American Association for the Study of Liver Diseases (AASLD):
View Official Guideline

Key Literature & References:

Evidence AASLD Practice Guidance on the Management of Complications of Cirrhosis